Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders

Patent metadata

Field	Value
Publication number	US-12410195-B2
Application number	US-202418741739-A
Country	US
Kind code	B2
Filing date	Jun 12, 2024
Priority date	Dec 11, 2019
Publication date	Sep 9, 2025
Grant date	Sep 9, 2025

Abstract

The invention relates to pharmaceutical compositions comprising the compound of Formula I,

and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D 2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

First claim

What is claimed:

1. A pharmaceutical composition comprising:
(i) a compound of Formula I:

in free base or pharmaceutically acceptable salt form; and

(ii) a compound of Formula II:

in free base or pharmaceutically acceptable salt form.

2. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises the compound of Formula I and the compound of Formula II in a weight ratio in the range of from 1:200 to 1:2000.

3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition comprises the compound of Formula I and the compound of Formula II in a weight ratio in the range of from 1:245 to 1:1000.

4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition comprises the compound of Formula I and the compound of Formula II in a weight ratio in the range of from 1:250 to 1:550.

5. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition comprises the compound of Formula I and the compound of Formula II in a weight ratio in the range of from 1:300 to 1:500.

6. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition comprises the compound of Formula I and the compound of Formula II in a weight ratio in the range of from 1:285 to 1:460.

7. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a tablet or a capsule.

8. The pharmaceutical composition according to claim 7 , wherein the compound of Formula II is in toluenesulfonic acid addition salt form.

9. The pharmaceutical composition according to claim 7 , wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable diluent or carrier in admixture with the compound of Formula I and the compound of Formula II.

10. The pharmaceutical composition according to claim 9 , wherein the pharmaceutically acceptable diluent or carrier is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), and (u):
(a) an anti-oxidant;
(b) a binder;
(c) a buffer;
(d) a colorant;
(e) a desiccant;
(f) a diluent;
(g) a disintegrant;
(h) a drying agent;
(i) a dye;
(j) an effervescent;
(k) a filler;
(l) a flavor;
(m) a glidant;
(n) a humectant;
(o) a lubricant;
(p) a plasticizer;
(q) a polymer;
(r) a surfactant;
(s) a sweetener;
(t) a thickening agent; and
(u) a wetting agent,
or a combination thereof.

11. The pharmaceutical composition according to claim 10 , wherein the pharmaceutically acceptable diluent or carrier is selected from the group consisting of (a), (b), (f), (g), (k), (m), (o), (s), and (t):
(a) an anti-oxidant;
(b) a binder;
(f) a diluent;
(g) a disintegrant;
(k) a filler;
(m) a glidant;
(o) a lubricant;
(s) a sweetener; and
(t) a thickening agent,
or a combination thereof.

12. The pharmaceutical composition according to claim 10 , wherein (a) the anti-oxidant is selected from the group consisting of ascorbic acid, butylated hydroxytoluene (BHT), citric acid, propyl gallate, and sodium metabisulfite.

13. The pharmaceutical composition according to claim 10 , wherein (b) the binder is selected from the group consisting of copovidone, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.

14. The pharmaceutical composition according to claim 10 , wherein (f) the diluent or (k) the filler is selected from the group consisting of cellulose, dicalcium phosphate, isomalt, lactose monohydrate, and mannitol.

15. The pharmaceutical composition according to claim 14 , wherein the cellulose is microcrystalline cellulose.

16. The pharmaceutical composition according to claim 15 , wherein the microcrystalline cellulose is silicified microcrystalline cellulose.

17. The pharmaceutical composition according to claim 10 , wherein (g) the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate.

18. The pharmaceutical composition according to claim 10 , wherein (m) the glidant is silicon dioxide or talc.

19. The pharmaceutical composition according to claim 10 , wherein (o) the humectant is glyceryl monostearate or magnesium stearate.

20. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition comprises croscarmellose sodium and mannitol.

21. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition comprises magnesium stearate and talc.

22. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition comprises croscarmellose sodium, mannitol, and magnesium stearate.

23. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition comprises croscarmellose sodium, mannitol, and talc.

24. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition comprises croscarmellose sodium, mannitol, magnesium stearate, and talc.

Assignees

• Intra Cellular Therapies Inc

Inventors

• Li Peng
• Davis Robert E
• Vanover Kimberly

Classifications

• C07D519/00 Primary

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title